Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Myelodysplastic syndrome

Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases

Leukemia volume 32, pages 2512–2518 (2018)Cite this article

Subjects

To the Editor,

Chronic myelomonocytic leukemia (CMML) is a clonal, hematopoietic stem cell disorder, characterized by sustained peripheral blood (PB) monocytosis and an inherent risk for blast phase (BP) disease [1, 2]. Blast phase, as defined by ≥20% PB or bone marrow (BM) blasts [1], has a reported incidence ranging from 15 to 29% [1, 2]. Risk factors for CMML-BP have included high-risk karyotype [3, 4], PB blast % [5, 6], circulating immature myeloid cells (IMCs) [6], absolute monocyte count (AMC) >10 × 10(9)/L [5, 6], ASXL1, RUNX1, NRAS, SETBP1, DNMT3A, and NPM1 mutations [6, 7]. In CMML, while predictors for BP have been identified, not much is known about prognostication, optimal treatment modalities, and survival outcomes. We carried out this large, collaborative, two institution study (Mayo Clinic, Minnesota and the MD Anderson Cancer Center, Texas) with the intent to examine (i) prognostic factors, (ii) survival trends, and (iii) treatment outcomes in patients with CMML-BP.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

    Article  CAS  Google Scholar 

  2. Patnaik MM, Wassie EA, Lasho TL, Hanson CA, Ketterling R, Tefferi A. Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome. Am J Hematol. 2015;90:411–6.

    Article  Google Scholar 

  3. Such E, Germing U, Malcovati L, Cervera J, Kuendgen A, Della Porta MG, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121:3005–15.

    Article  CAS  Google Scholar 

  4. Wassie EA, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study. Am J Hematol. 2014;89:1111–5.

    Article  CAS  Google Scholar 

  5. Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013;27:1504–10.

    Article  CAS  Google Scholar 

  6. Patnaik MM, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014;28:2206–12.

    Article  CAS  Google Scholar 

  7. Patnaik MM, Barraco D, Lasho TL, Finke CM, Hanson CA, Ketterling RP, et al. DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. Am J Hematol. 2017;92:56–61.

    Article  CAS  Google Scholar 

  8. Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31:2428–36.

    Article  CAS  Google Scholar 

  9. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

    Article  Google Scholar 

  10. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–25.

    Article  CAS  Google Scholar 

  11. Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, et al. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood. 2015;125:1857–65.

    Article  CAS  Google Scholar 

  12. Patnaik MM, Lasho TL, Vijayvargiya P, Finke CM, Hanson CA, Ketterling RP, et al. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J. 2016;6:e385.

    Article  CAS  Google Scholar 

  13. Merlevede J, Droin N, Qin T, Meldi K, Yoshida K, Morabito M, et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat Commun. 2016;7:10767.

    Article  CAS  Google Scholar 

Download references

Funding:

Current publication is supported in part by grants from the “The Gerstner Family Career Development Award” and the Mayo Clinic Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA”. This publication was supported by CTSA Grant Number KL2 TR000136 from the National Center for Advancing Translational Science (NCATS). This work is supported in part by the University of Texas MD Anderson Cancer Center Support Grant CA016672, the University of Texas MD Anderson MDS/AML Moon Shot, and the MDS Clinical Research Consortium, which is funded by the Edward P. Evans Foundation.

Author information

Authors and Affiliations

  1. Mayo Clinic, Rochester, MN, USA

    Mrinal M. Patnaik, Rangit Vallapureddy, Fevzi F. Yalniz, Terra Lasho, Curtis A. Hanson, Rhett P. Ketterling & Ayalew Tefferi

  2. MD Anderson Cancer Center, Houston, TX, USA

    Ana A. Pierola, Tapan M. Kadia, Elias J. Jabbour, Hagop M. Kantarjian & Guillermo Garcia-Manero

Authors
  1. Mrinal M. Patnaik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ana A. Pierola
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rangit Vallapureddy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fevzi F. Yalniz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tapan M. Kadia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elias J. Jabbour
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Terra Lasho
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Curtis A. Hanson
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rhett P. Ketterling
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hagop M. Kantarjian
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ayalew Tefferi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Guillermo Garcia-Manero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mrinal M. Patnaik.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patnaik, M.M., Pierola, A.A., Vallapureddy, R. et al. Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. Leukemia 32, 2512–2518 (2018). https://doi.org/10.1038/s41375-018-0143-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-018-0143-8

Search

Advanced search

Quick links